1. Jaiyesimi IA, et al. J Clin Oncol. 2024;42:e1-e22. 2. Li H, et al. Cancers. 2024;16(4):744. 3. TRODELVY® (sacituzumab govitecan-hziy) [summary of product characteristics]. Carrigtohill, Ireland: Gilead Sciences Ireland UC; July 2023. 4. Paz-Ares LG, et al. J Clin ...
Sandip P. Patel, MD, reviews data from the preliminary results of the EVOKE-02 study investigating sacituzumab govitecan plus pembrolizumab in first-line metastatic non–small cell lung cancer. This is a modal window. The Playback API request failed for a...
被引量: 0发表: 2024年 60P Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC): Efficacy results by histology from the EVOKE-02 study Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non...
戈沙妥珠单抗是全球首款获批的TROP2 ADC药物,此前已被获批用于乳腺癌与尿路上皮癌的治疗,但在非小细胞肺癌上的探索中遭遇失利,其后续研究值得关注。 ▌CONTACT-02(NCT04446117)研究 推荐理由:卡博替尼联合阿替利珠单抗用于二线去势抵抗前列腺癌(CRPC)的III期注册性临床试验CONTACT-02研究数据披露,联合用药组中位PFS...
ESMO Open Volume 9, Supplement 3, March 2024, 10263960P Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC): Efficacy results by histology from the EVOKE-02 study Author links open overlay panelF. Cappuzzo 1, J. Patel 2...
公告 Evoke Pharma Inc|3:首次持股声明 发表于 2024-11-16 05:36 277次浏览 分享 评论 赞 公告 Evoke Pharma Inc|SC 13G:5%以上股东持股变动公告 发表于 2024-11-15 02:14 295次浏览 分享 评论 赞 公告 Evoke Pharma Inc|SC 13G:5%以上股东持股变动公告 发表于 2024-11-14 22:24 280次浏览 分享...
02:19 14:54 02:19 03:04 01:23 12:01 萌新开荒(斗武大会) 12024-8-15 16:47 92024-8-15 02:15 10:53 07:26 03:22 05:57 11:21 00:31 00:45 00:25 05:21 07:56 00:25 06:43 07:05 00:31 05:55 02:49 02:10 06:32 ...
推荐理由:卡博替尼联合阿替利珠单抗用于二线去势抵抗前列腺癌(CRPC)的III期注册性临床试验CONTACT-02研究数据披露,联合用药组中位PFS达6.3个月,患者疾病进展或死亡风险降低35%。PD1/PDL1单抗类药物在CRPC上的探索颇为坎坷,单独使用或联合疗法的II期或III期临床试验以失败居多。此次以卡博替尼+阿替利珠单抗组合取得...
被引量: 0发表: 2024年 Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02. Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell ...